Evidence map›Paper›PMID 39382621›Full record

ArticleAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2024

SGLT2 Inhibitor Prescribing in Cardiovascular-Kidney-Metabolic Syndrome.

Brandon D Beers, Bhavya Chebrolu, Gretchen M Stern, Leo F Buckley, Muthiah Vaduganathan, Deepak L Bhatt, Thomas D Bernier

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Brandon D BeersDepartment of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.
Bhavya ChebroluDepartment of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.
Gretchen M SternDepartment of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.
Leo F BuckleyDepartment of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.
Muthiah VaduganathanDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Deepak L BhattIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Thomas D BernierDepartment of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA. thomas_bernier@rush.edu.

Funding

Inflammasome Activity as a Potential Contributor to Uremic CardiomyopathyK23HL150311 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BUCKLEY, LEO FRANCIS · 2020 to 2024
$1.1M
NHLBI NIH HHS K23 HL150311NHLBI NIH HHS K23HL150311
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CardiometabolicPrescribingSodium-glucose cotransporter-2 inhibitors

Identifiers

PMID39382621
PMCPMC11904812

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.